The BNP Assisted Teatment to Lessen Serial Cardiac Readmissions and Death.

Completed

• Conditions: Heart Failure; Cardiovascular - Other cardiovascular diseases

• Registration Number: ACTRN12605000735651
• Lead Sponsor: Health Research Council of New Zealand

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2005-11-11
• Study Completion: 2020-10-31
• Last Update Posted: 2 September 2024

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 363

Inclusion Criteria

Symptomatic congestive HF as defined by Framingham criteria (Table 1), requiring admission to hospital in subjects able to give competent informed consent.

Exclusion Criteria

Active myocarditis/pericarditis.Under active consideration for cardiac transplantation. Life expectancy due to non-cardiovascular disease <24 months.Severe hepatic or pulmonary disease (FEV1 <1L).Renal impairment with creatinine at discharge from index admission >0.25mmol/L.Transient HF in association with myocardial infarction treated with acute revascularisation and subsequent ejection fraction during index admission >40%.Severe valvular disease being considered for surgery, or severe aortic stenosis (valve area <1cm2), or symptoms of HF secondary to mitral stenosis.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To determine the effect of hormone-guidance of treatment of heart failure on clinical outcomes.[ ]

Secondary Outcome Measures

Name	Time	Method
(b) To determine the effect of hormone-guidance of treatment of heart failure on outcomes in subjects <75 years of age.[ ];(c) To determine the effect of standardised regular intensified follow-up on outcomes in heart failure.[ ];(d) To determine the plasma levels and changes in these concentrations over time of Ucn-I and urotensin-II in subjects with heart failure and relate these plasma concentrations to cardiac structure and function and subsequent clinical outcome.[ ];e) To assess the prognostic importance of newer echocardiographic measures of diastolic function in subjects with heart failure and changes in these parameters over time in this population.[ ]